BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026

BridgeBio Pharma, Inc. (BBIO)

We couldn't retrieve the full text for this release. Read it on the company's site.